An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib.

Trial Profile

An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib.

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use
  • Acronyms SUNPAZ
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Feb 2017 Results presented at the 2017 Genitourinary Cancers Symposium
    • 27 May 2016 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 25 Mar 2014 Planned End Date changed from 1 Sep 2015 to 1 May 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top